A scorecard for osteoporosis in Canada and seven Canadian provinces
Authors:
Open Access
- 25 July 2020
- journal article
- research article
- Published by Springer Nature in Osteoporosis International
- Vol. 32 (1) , 123-132
Abstract
Summary The scorecard evaluates the burden and management of osteoporosis in Canada and how care pathways differ across Canadian provinces. The results showed there are inequities in patients’ access to diagnosis, treatment, and post-fracture care programs in Canada. Interventions are needed to close the osteoporosis treatment gap and minimize these inequities. Introduction The purpose of this study was to develop a visual scorecard that assesses the burden of osteoporosis and its management within Canada and seven Canadian provinces. Methods We adapted the Scorecard for Osteoporosis in Europe (SCOPE) to score osteoporosis indicators for Canada and seven provinces (British Columbia, Alberta, Saskatchewan, Ontario, Quebec, New Brunswick, and Newfoundland). We obtained data from a comprehensive literature review and interviews with osteoporosis experts. We scored 20 elements across four domains: burden of disease, policy framework, service provision, and service uptake. Each element was scored as red, yellow, or green, indicating high, intermediate, or low risk, respectively. Elements with insufficient data were scored black. Results Canada performed well on several elements of osteoporosis care, including high uptake of risk assessment algorithms and minimal wait times for hip fracture surgery. However, there were no established fracture registries, and reporting on individuals with high fracture risk who remain untreated was limited. Furthermore, osteoporosis was not an official health priority in most provinces. Government-backed action plans and other osteoporosis initiatives were primarily confined to Ontario and Alberta. Several provinces (Saskatchewan, New Brunswick, Newfoundland) did not have any registered fracture liaison service (FLS) programs. Access to diagnosis and treatment was also inconsistent and reimbursement policies did not align with clinical guidelines. Conclusion Government-backed action plans are needed to address provincial inequities in patients’ access to diagnosis, treatment, and FLS programs in Canada. Further characterization of the treatment gap and the establishment of fracture registries are critical next steps in providing high-quality osteoporosis care.Keywords
Funding Information
- Amgen Canada (Not applicable)
This publication has 26 references indexed in Scilit:
- Direct health-care costs attributed to hip fractures among seniors: a matched cohort studyOsteoporosis International, 2012
- A systematic review of hip fracture incidence and probability of fracture worldwideOsteoporosis International, 2012
- The burden of illness of osteoporosis in CanadaOsteoporosis International, 2012
- Atypical femur fractures: a review of the evidence and its implication to clinical practiceTherapeutic Advances in Musculoskeletal Disease, 2011
- Femoral Insufficiency Fractures Associated with Prolonged Bisphosphonate TherapyClinical Orthopaedics and Related Research, 2010
- 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summaryCanadian Medical Association Journal, 2010
- Peak bone mass from longitudinal data: Implications for the prevalence, pathophysiology, and diagnosis of osteoporosisJournal of Bone and Mineral Research, 2010
- Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate ExposureJournal of Oral and Maxillofacial Surgery, 2010
- Repeat Low-Trauma Fractures Occur Frequently Among Men and Women Who Have Osteopenic BMDJournal of Bone and Mineral Research, 2009
- Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025Journal of Bone and Mineral Research, 2007